Overview

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of DVS SR (25 and 50 mg/day) in the treatment of adults with Major Depressive Disorder. The study will also assess changes in sexual function and general and functional quality of life outcomes.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Treatments:
Desvenlafaxine Succinate